Bryan Yoon
Geschäftsführer bei TERNS PHARMACEUTICALS, INC.
Vermögen: 426 602 $ am 30.04.2024
Aktive Positionen von Bryan Yoon
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TERNS PHARMACEUTICALS, INC. | Geschäftsführer | 01.11.2020 | - |
General Counsel | 01.11.2020 | - | |
Unternehmenssekretär | 01.01.2021 | - |
Karriereverlauf von Bryan Yoon
Ehemalige bekannte Positionen von Bryan Yoon
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LOGICBIO THERAPEUTICS, INC. | Verwaltungsdirektor | 01.11.2019 | 06.11.2020 |
General Counsel | 01.11.2019 | 06.11.2020 | |
Unternehmenssekretär | 01.11.2019 | 06.11.2020 | |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | 08.01.2018 | 07.06.2019 |
NIGHTSTAR THERAPEUTICS PLC | General Counsel | 01.11.2017 | 01.06.2019 |
Unternehmenssekretär | 01.02.2018 | 01.06.2019 | |
INTERCEPT PHARMACEUTICALS, INC. | General Counsel | 01.01.2013 | 01.11.2017 |
Unternehmenssekretär | 01.01.2013 | 01.11.2017 |
Ausbildung von Bryan Yoon
Cornell University | Graduate Degree |
The University of Michigan Law School | Graduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Vereinigtes Königreich | 3 |
2 |
Operativ
General Counsel | 4 |
Corporate Secretary | 4 |
Graduate Degree | 2 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Nightstar Therapeutics Ltd.
Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
LogicBio Therapeutics, Inc.
LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Terns Pharmaceuticals, Inc. |
- Börse
- Insiders
- Bryan Yoon
- Erfahrung